Among 320 patients with lower extremity peripheral artery disease (PAD) and low-density lipoprotein-cholesterol (LDL-C) levels > 70 mg/dl, we determined whether male sex, higher education, and greater self-efficacy for willingness to request therapy from one's physician were associated with increases in LDL-C-lowering medication and achievement of an LDL-C level < 70 mg/dl at 1-year follow-up. Participants were enrolled in a randomized controlled clinical trial to determine whether a telephone counseling intervention can help PAD patients achieve an LDL-C level < 70 mg/ dl, compared to usual care and attention control conditions, respectively. Adjusting for age, race, comorbidities, PAD severity, and other covariates, male sex (odds ratio = 3.33, 95% confidence interval = 1.64 to 6.77, p = 0.001) was associated with a higher likelihood of adding cholesterol-lowering medication during follow-up, but was not associated with achieving an LDL-C < 70 mg/dl (odds ratio = 1.09, 95% confidence interval = 0.55 to 2.18). No associations of education level or self-efficacy with study outcomes were identified. In conclusion, male PAD patients with baseline LDL-C levels ≥ 70 mg/dl were more likely to intensify LDL-C-lowering medication during 1-year follow-up than female PAD patients. Despite greater increases in LDL-C-lowering medication among female PAD patients, there was no difference in the degree of LDL-C lowering during the study between men and women with PAD. Clinical Trial Registration -
Introduction
Men and women with lower extremity peripheral artery disease (PAD) have greater cardiovascular morbidity and mortality than people without PAD. 1, 2 Although treatment to reduce low-density lipoprotein-cholesterol (LDL-C) reduces the rate of cardiovascular events in PAD, 3 patients with PAD are less likely to achieve recommended LDL-C levels and less likely to take cholesterol-lowering medication than patients with coronary artery disease. [4] [5] [6] [7] Reasons for less intensive treatment of LDL-C in patients with PAD, compared to other high-risk patients, are unclear.
Among participants in a randomized controlled clinical trial designed to help PAD patients with suboptimal LDL-C levels achieve an LDL-C < 70 mg/dl, 8 we studied the characteristics of PAD patients who were more likely to achieve an ideal LDL-C level, compared to those less likely to achieve an ideal LDL-C level. The intervention of this clinical trial was a telephone counseling intervention designed to encourage patients with PAD to discuss their cholesterol-lowering therapy and request more intensive LDL-C-lowering medication from their physician. We determined whether male sex, higher education levels, and greater self-efficacy regarding patient willingness to request medical therapies from their physician were associated with greater increases in LDL-lowering medication and achievement of an LDL-C level less than 70 mg/dl at 1-year follow-up, compared to female sex, lower education levels, and lower self-efficacy for willingness to request medical therapies, respectively.
Methods

Design overview
The main study was a randomized controlled clinical trial designed to determine whether a telephone counseling intervention could help patients with PAD who had baseline LDL-C levels > 70 mg/dl achieve greater LDL-C reduction compared to two control conditions. 8, 9 The institutional review boards of participating medical centers approved the protocol. Participants gave written informed consent. The study design was a 1-year randomized controlled clinical trial with three parallel conditions: telephone counseling intervention, attention control condition, or usual care. The primary outcome was change in LDL-C level between baseline and 12-month follow-up. The study was conducted at Northwestern University Feinberg School of Medicine in Chicago, IL and the University of Massachusetts Medical School (UMASS) in Worcester, MA between 1 February 2006 and 30 September 2009.
Setting and participants
In Chicago, participants were identified from among PAD patients receiving care at Chicago-area hospitals. Newspaper and radio advertisements, posted signs, community presentations, bulk mailings to men and women aged 65 years and older, and letters mailed to participants with PAD identified in the national Life Line screening program were used for recruitment in Chicago. 9 PAD participants who completed research studies at Northwestern more than 3 months previously were invited to participate. In Worcester, recruitment consisted of mailed letters to patients with PAD, newspaper advertisements, and posted flyers. 9 Inclusion criteria were presence of PAD and an LDL-C ≥ 70 mg/dl. An LDL-C ≥ 70 mg/dl was selected based on recent recommendations regarding LDL-C-lowering therapy in patients at high risk for cardiovascular events. 10 PAD was defined as one or more of the following: an ankle-brachial index (ABI) < 0.95 at the baseline visit, documented lower extremity revascularization, an angiogram demonstrating ≥ 50% obstruction in at least one lower extremity artery, or a certified non-invasive vascular laboratory report documenting PAD.
Exclusion criteria were lack of a physician, life expectancy less than 1 year, inability to return for follow-up testing, ongoing participation in another clinical trial, change in prescribed cholesterol-lowering medication within the past 3 months, and inability to tolerate cholesterol-lowering medications. Because an exploratory aim was to help participants increase their physical activity, potential participants who had critical limb ischemia, were wheelchairbound, or had an above or below-knee amputation were excluded.
ABI measurement
A hand-held Doppler probe (Nicolet Vascular Pocket Dop II; Nicolet Biomedical Inc., Golden, CO, USA) was used to obtain systolic pressures in the right and left brachial, dorsalis pedis, and posterior tibial arteries. 8, 9 For each leg, the ABI was calculated by dividing the higher of the dorsalis pedis and posterior tibial pressures by the higher of the brachial pressures.
Medical history
Medical history, race, and demographics were obtained using standardized questionnaires and patient report. 9, 11 Randomization After baseline testing, eligible participants were randomized using block stratified randomization. Block sizes were three, six, and nine. 12, 13 Randomization was stratified by site (Chicago versus Worcester). Differences in the proportion of females across study conditions were observed during the first Data Safety and Monitoring Board meeting after recruitment began. Therefore, randomization was additionally stratified by sex beginning 30 January 2007. Stratifying randomization by sex did not influence eligibility criteria or recruitment methods.
Study conditions
Intervention condition. The intervention consisted of telephone-delivered, patient-centered counseling designed to encourage participants with PAD to discuss their LDL-C level with their physician and request more intensive LDL-C-lowering therapy. 8 Intervention telephone calls lasted approximately 25 minutes and were delivered every 6 weeks, for a total of eight calls. First, the counselor educated participants about the importance of LDL-lowering. Next, the counselor assessed whether participants were taking cholesterol-lowering medication and (when relevant) whether they were adherent to their medication. If participants reported taking less than 80% of prescribed cholesterol-lowering medication, the counselor helped them increase adherence using patient-centered counseling. If participants reported no prescribed cholesterol-lowering medication, the counselor encouraged them to request it from their physician. If participants reported adherence to prescribed cholesterol-lowering medication, the counselor encouraged them to request more intensive cholesterollowering medication from their physician. Counselors did not typically recommend a specific cholesterol-lowering medication. However, in certain circumstances, specific cholesterol-lowering medications were discussed with individual participants, such as when an LDL-C < 70 mg/dl was not achieved on the highest dose of a low-potency statin or when a participant had side effects associated with statin medications. Thus, these individualized cholesterollowering medication discussions could include statin and/ or non-statin medications. Follow-up calls assessed progress toward goals established during the previous call and continued to emphasize increases in cholesterol-lowering therapy or cholesterol-lowering medication adherence until an LDL-C < 70 mg/dl was achieved.
Attention control condition. The attention control condition consisted of eight telephone calls, lasting approximately 25 minutes, delivered every 6 weeks. 8 Topics of these telephone calls included risk factors for PAD, PAD symptoms, and interventional procedures for PAD. Calls were delivered by people distinct from those delivering the intervention.
Usual care condition. Participants randomized to usual care received no scheduled telephone calls.
Low-density lipoprotein-cholesterol
Blood specimens were obtained after fasting and processed immediately for storage at ≤ −70°C. Specimens were mailed in batches to a central core laboratory within 1 month of collection. LDL-C was measured using a homogenous direct method. 14 First, a specific detergent was used to solubilize non-LDL lipoproteins. Next, another detergent solubilized LDL-C in order to measure the cholesterol component enzymatically. Day-to-day variability of LDL-C at concentrations of 90, 106, and 129 mg/dl was below 3.1%.
Measures of self-efficacy for willingness to request treatments from physicians
Because the intervention was designed to help patients with PAD request more intensive LDL-C-lowering therapy from their physicians, we hypothesized that patients with more self-efficacy regarding willingness to request therapies from their physician would be more likely to increase their LDL-C-lowering medication during the study. Therefore, two questionnaires were administered at the baseline visit to assess participants' self-efficacy regarding their inclination to request therapies from their physician. These questionnaires were the Perceived Efficacy in Patient-Physician Interactions (PEPPI) and the Patient Activation Measure (PAM). 15, 16 The PEPPI questionnaire measures patients' self-efficacy regarding their ability to: (a) know what questions to ask a physician; (b) get a physician to answer all of their questions; (c) make the most of their physician visit; (d) get a physician to take their chief health concern seriously; and (e) get a physician to do something about their chief health concern. 15 Scores range from zero to 50 (50 = best).
The 13-item PAM, scored on a 0-100 scale (100 = best), assesses: (a) the degree to which patients believe it is important for them to influence their health care; (b) patient confidence in their ability to influence their healthcare; (c) the degree to which patients take action to influence their healthcare; and (d) patient confidence that they can continue to affect their healthcare, even under stress. 16 
Additional measures
Participant health knowledge and presence of depressive symptoms were included in our adjusted models as covariates. Both were administered at the baseline study visit with the PEPPI and PAM.
Health knowledge. A 27-item questionnaire was developed to measure participants' knowledge regarding the association of PAD with cardiovascular events, the importance of LDL-C lowering, the ability of patients to influence physician behavior, ideal LDL-C levels, and characteristics of an LDL-C-lowering diet. A percent score ranging from 0 to 100% was calculated for each participant. Cronbach's alpha for this questionnaire was 0.84. 9
Geriatric Depression Scale. We administered the Geriatric Depression Scale Short Form (GDS-S) at baseline to assess depressive symptoms. 17 Measuring changes in prescribed medications. Participants were asked to bring all medications to each study visit. Cholesterol-lowering medications and doses were recorded. Changes in cholesterol-lowering medication between baseline and follow-up were assessed in a blinded fashion. An increase in medication intensity was defined as the addition of a cholesterol-lowering medication or an increase in dose of a cholesterol-lowering medication. When participants changed the specific cholesterol-lowering medication they were taking between baseline and follow-up, two investigators (MMM and ISO), blinded to all other patient characteristics, determined whether the change represented an increase in intensity of LDL-C-lowering therapy. [18] [19] [20] Disagreements were resolved by discussion.
Statistical analyses
We used chi-square tests for categorical variables and oneway analyses of variance for continuous variables to compare baseline characteristics between participants with versus without an increase in LDL-C-lowering medication at 1-year follow-up and between participants with versus without an LDL-C less than 70 mg/dl at 1-year follow-up. Similar methods were used to compare age, race, education, self-efficacy measures, health knowledge, and other study measures between men and women participants with PAD. Logistic regression analyses were used to determine whether male sex, higher levels of education, and higher scores at baseline on the PAM and PEPPI scales were associated with an increase in LDL-C medication and achievement of LDL-C < 70 mg/dl at 1-year follow-up, respectively, adjusting for age, race, baseline LDL-C level, ABI < 0.50, comorbidities, use of a cholesterol-lowering medication at baseline, baseline GDS score, baseline health knowledge scores, and randomized study group. A priori, a p-value < 0.05 was considered statistically significant. 
Results
Participation and exclusion rates have been reported. 8, 9 Of the 355 participants randomized, LDL-C levels were obtained at 12-month follow-up for 85.8%, 92.5%, and 90.2% of participants in the intervention, attention control, and usual care conditions, respectively (p = 0.243). A total of 320 PAD participants had 12-month LDL-C levels and were included in the current analyses. The mean age was 70.0 ± 10.4, mean ABI was 0.69 ± 0.16, and mean baseline LDL-C was 103.7 mg/dl ± 31.6. The PAD participants included 38.9% females and 15.1% African Americans. Compared to women with PAD, men with PAD were younger and had higher baseline prevalences of coronary revascularization and diabetes mellitus ( Table 1) .
At 12-month follow-up, mean changes in LDL-C were −17.1, −6.7, and −12.3 mg/dl in the intervention, attention control, and usual care conditions, respectively (overall p-value = 0.040). At 12-month follow-up, participants in the intervention significantly improved their LDL-C level, compared to those in attention control (-17.1 vs −6.7 mg/ dl, p = 0.012) but not compared to usual care (-17.1 vs −12.3 mg/dl, p = 0.244). Participants in the intervention had greater increases in cholesterol-lowering medication than participants in the attention control and usual care conditions, respectively (+49% vs +18% vs +32%, p < 0.001).
Overall, 99 (34%) of 295 participants with data on cholesterol medication use at 12-month follow-up increased their LDL-C-lowering medication during the study ( Table  2) . Participants who increased their LDL-C-lowering medication had an LDL-C change of −28.63 mg/dl versus −3.90 mg/dl for those who did not increase their LDL-C-lowering medication (p < 0.0001).
In unadjusted analyses, PAD participants who increased their LDL-C medication included a higher proportion of men and had higher baseline LDL-C levels than those who did not increase their LDL-C-lowering medication ( Table 2 ). There were no significant associations of higher baseline education level, higher PEPPI scores, or higher PAM scores with increasing LDL-C-lowering medication ( Table 2) .
Overall, 78 (25%) of 309 participants achieved an LDL-C level < 70 mg/dl at 12-month follow-up (Table 3) . In unadjusted analyses, lower baseline LDL-C, history of myocardial infarction, and history of coronary revascularization were each associated with achieving an LDL-C level < 70 mg/dl (Table 3) .
Adjusting for covariates shown in Table 4 , participants randomized to the intervention were more likely to increase their cholesterol-lowering medication, compared to usual care. Male sex (p < 0.001) and higher baseline LDL-C levels (p < 0.001) were also associated with increasing The dependent variable of interest is achieving a low-density lipoprotein-cholesterol level of < 70 mg/dl at 12-month follow-up. Covariates are the clinical characteristics listed in Table 5 . LDL-C, low-density lipoprotein-cholesterol; ABI, ankle-brachial index; PAM, Patient Activation Measure; PEPPI, Perceived Efficacy in Patient-Physician Interactions; GDS, Geriatric Depression Scale.
LDL-C-lowering medication during follow-up (Table 4 ). There were no significant associations of higher baseline education level, higher PAM scores, or higher PEPPI scores with increasing cholesterol-lowering medication. Adjusting for the covariates shown in Table 5 , there were no significant associations of male sex, higher baseline education level, higher PEPPI scores, or PAM scores with achieving an LDL-C < 70 mg/dl at 12-month followup. Lower baseline LDL-C levels (p < 0.001) were associated independently with the outcome of achieving an LDL-C level < 70 mg/dl during follow-up (Table 5 ).
Discussion
Although LDL-C-lowering therapy reduces cardiovascular event rates in PAD, 3 patients with PAD are less likely to achieve recommended LDL-C levels and are less likely to take cholesterol-lowering medication than patients with coronary artery disease. [4] [5] [6] [7] Reasons for less intensive treatment of LDL-C in patients with PAD as compared to other high-risk patients are unclear. We studied whether male sex, higher education level, and greater self-efficacy for requesting therapies from one's physician were associated with intensifying cholesterol-lowering medication and achieving an LDL-C < 70 mg/dl in 320 PAD participants enrolled in a randomized controlled clinical trial designed to help patients with PAD achieve lower LDL-C levels. The telephone counseling intervention was designed to help PAD patients request more intensive LDL-C-lowering therapy from their physician. After adjusting for the study condition and other covariates, male sex and higher baseline LDL-C levels were each associated independently with increasing cholesterol-lowering medication at 1-year follow-up.
It is important to point out that although women were less likely to have their cholesterol-lowering medication increased during the 1-year follow-up period, there were no gender differences in the likelihood of achieving an LDL-C level < 70 mg/dl. Higher education and greater self-efficacy for requesting therapies from one's physician were not associated with increases in LDL-C-lowering medication or achieving an LDL-C < 70 mg/dl during the 1-year intervention. To our knowledge, this is the first study to prospectively assess patient characteristics associated with increasing LDL-C-lowering medication or achieving a target LDL-C level among patients with PAD. Future study is needed to identify mechanisms of the gender differences in the cholesterol-lowering therapy reported here.
The prevalence of cholesterol-lowering medication use in this trial was higher than previously reported rates of cholesterol-lowering medication use in an observational study of patients with PAD. Seventy-five percent of the PAD participants in this trial reported taking at least one cholesterol-lowering medication at baseline, whereas a report published in 1997 demonstrated that only 46% of PAD participants with hypercholesterolemia were taking a cholesterol-lowering medication. 21 PAD participants in this prior observational study were identified from the noninvasive vascular laboratory at an academic medical center in Chicago, which was also a recruitment source in Chicago for participants in the current study. Therefore, rates of cholesterol-lowering medication use in patients with PAD appear to be increasing over time. Our results may have been different with lower baseline use of cholesterol-lowering medication.
Although we designed our intervention to educate PAD patients about the importance of LDL-C lowering and to assist PAD patients with requesting LDL-C-lowering therapy from their physician, we found no associations of our baseline measures of health knowledge or self-efficacy regarding willingness to request therapies from physicians with study outcomes. Thus, better health knowledge and greater self-efficacy for requesting therapies from one's physician may not influence receipt of optimal cholesterollowering therapy in patients with PAD. Consistent with these results, although women had a higher baseline PAM score, consistent with greater self-efficacy for influencing their own healthcare, they were less likely than men to have their LDL-C-lowering medication increased during the trial.
This study has limitations. First, findings are generalizable to PAD patients who share characteristics of those eligible and willing to participate in this randomized controlled clinical trial. Second, our results may be influenced by residual confounding from the study interventions. Third, we did not assess the attitudes of the treating physicians regarding an LDL-C goal < 70 mg/dl for patients with PAD. Thus, our study design does not allow us to discern the degree to which physician attitudes toward the LDL-C < 70 mg/dl target influenced our results.
In conclusion, among PAD patients with suboptimal cholesterol levels enrolled in a randomized clinical trial, men were more likely than women to increase their cholesterollowering medication. Despite greater increases in LDL-Clowering medication among female PAD patients, there was no difference in the degree of LDL-C lowering during the trial between men and women with PAD. Further research is needed to identify mechanisms of these associations and to achieve ideal LDL-C levels in all patients with PAD.
